This article will reflect on the compensation paid to Mihael Polymeropoulos who has served as CEO of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) since 2003. This analysis will also look to assess whether the CEO is appropriately paid, considering recent earnings growth and investor returns for Vanda Pharmaceuticals.
How Does Total Compensation For Mihael Polymeropoulos Compare With Other Companies In The Industry?
Our data indicates that Vanda Pharmaceuticals Inc. has a market capitalization of US$675m, and total annual CEO compensation was reported as US$4.3m for the year to December 2019. That's just a smallish increase of 6.3% on last year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$721k.
For comparison, other companies in the same industry with market capitalizations ranging between US$400m and US$1.6b had a median total CEO compensation of US$2.5m. This suggests that Mihael Polymeropoulos is paid more than the median for the industry. Furthermore, Mihael Polymeropoulos directly owns US$14m worth of shares in the company, implying that they are deeply invested in the company's success.
Talking in terms of the industry, salary represented approximately 25% of total compensation out of all the companies we analyzed, while other remuneration made up 75% of the pie. In Vanda Pharmaceuticals' case, non-salary compensation represents a greater slice of total remuneration, in comparison to the broader industry. It's important to note that a slant towards non-salary compensation suggests that total pay is tied to the company's performance.
A Look at Vanda Pharmaceuticals Inc.'s Growth Numbers
Vanda Pharmaceuticals Inc.'s earnings per share (EPS) grew 89% per year over the last three years. In the last year, its revenue is up 10%.
Overall this is a positive result for shareholders, showing that the company has improved in recent years. This sort of respectable year-on-year revenue growth is often seen at a healthy, growing business. Moving away from current form for a second, it could be important to check this free visual depiction of what analysts expect for the future.
Has Vanda Pharmaceuticals Inc. Been A Good Investment?
Since shareholders would have lost about 12% over three years, some Vanda Pharmaceuticals Inc. investors would surely be feeling negative emotions. Therefore, it might be upsetting for shareholders if the CEO were paid generously.
As we noted earlier, Vanda Pharmaceuticals pays its CEO higher than the norm for similar-sized companies belonging to the same industry. However, we must not forget that the EPS growth has been very strong, but it's disappointing to see negative shareholder returns over the same period. Although we don't think the CEO pay is too high, considering negative investor returns, it is more generous than modest.
CEO compensation can have a massive impact on performance, but it's just one element. We did our research and spotted 2 warning signs for Vanda Pharmaceuticals that investors should look into moving forward.
Switching gears from Vanda Pharmaceuticals, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.
If you decide to trade Vanda Pharmaceuticals, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted
Valuation is complex, but we're helping make it simple.
Find out whether Vanda Pharmaceuticals is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email firstname.lastname@example.org.